(PCRX) Pacira BioSciences - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 919m USD | Total Return: -10.5% in 12m
Avg Turnover: 12.2M
EPS Trend: -16.0%
Qual. Beats: 0
Rev. Trend: 98.8%
Qual. Beats: 1
Warnings
P/E ratio 179.6
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
Pacira BioSciences, Inc. (PCRX) specializes in the development and commercialization of non-opioid pain management and regenerative health solutions. Its primary product portfolio includes EXPAREL, an injectable suspension for postsurgical pain, ZILRETTA for osteoarthritis-related knee pain, and the iovera system, a handheld cryoanalgesia device. The company is also advancing PCRX-201, an intra-articular gene therapy candidate designed for long-term treatment of inflammatory joint conditions.
The company operates within the specialty pharmaceuticals sector, focusing on the high-demand niche of opioid-sparing analgesics to mitigate the risks associated with traditional narcotic pain relief. Pacira utilizes a proprietary multivesicular liposome (pMVL) drug delivery technology, which allows for the extended release of medications at the surgical site or joint, extending therapeutic effects without systemic toxicity.
Analyzing the long-term valuation metrics on ValueRay can provide deeper insights into the companys financial health.
Beyond human health, Pacira maintains a commercialization agreement for NOCITA, extending its bupivacaine liposome technology into the veterinary market. This diversified approach leverages existing manufacturing infrastructure to address pain management across both clinical and animal health segments.
- EXPAREL revenue growth hinges on Medicare reimbursement changes and hospital adoption rates
- Loss of patent protection for EXPAREL threatens long-term market exclusivity and margins
- ZILRETTA sales expansion depends on penetration of the chronic osteoarthritis pain market
- Pipeline advancement of PCRX-201 gene therapy determines long-term valuation and diversification
- Shifting surgical volumes and opioid reduction mandates drive demand for non-opioid alternatives
| Net Income: 5.14m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 0.93 > 1.0 |
| NWC/Revenue: 55.27% < 20% (prev 63.35%; Δ -8.08% < -1%) |
| CFO/TA 0.12 > 3% & CFO 142.2m > Net Income 5.14m |
| Net Debt (252.5m) to EBITDA (118.4m): 2.13 < 3 |
| Current Ratio: 4.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.9m) vs 12m ago -12.07% < -2% |
| Gross Margin: 79.34% > 18% (prev 0.78%; Δ 7.86k% > 0.5%) |
| Asset Turnover: 52.58% > 50% (prev 44.29%; Δ 8.29% > 0%) |
| Interest Coverage Ratio: 1.83 > 6 (EBITDA TTM 118.4m / Interest Expense TTM 14.9m) |
| A: 0.34 (Total Current Assets 515.0m - Total Current Liabilities 108.8m) / Total Assets 1.21b |
| B: -0.16 (Retained Earnings -196.4m / Total Assets 1.21b) |
| C: 0.02 (EBIT TTM 27.2m / Avg Total Assets 1.40b) |
| D: -0.35 (Book Value of Equity -192.9m / Total Liabilities 554.6m) |
| Altman-Z'' = 1.44 = BB |
| DSRI: 1.15 (Receivables 125.6m/104.7m, Revenue 734.9m/702.8m) |
| GMI: 0.98 (GM 79.34% / 77.61%) |
| AQI: 1.11 (AQ_t 0.43 / AQ_t-1 0.39) |
| SGI: 1.05 (Revenue 734.9m / 702.8m) |
| TATA: -0.11 (NI 5.14m - CFO 142.2m) / TA 1.21b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of May 30, 2026, the stock is trading at USD 23.22 with a total of 511,332 shares traded.
Over the past week, the price has changed by -1.11%,
over one month by -7.64%,
over three months by +5.98% and
over the past year by -10.45%.
Pacira BioSciences has received a consensus analysts rating of 3.86. Therefore, it is recommended to buy PCRX.
- StrongBuy: 3
- Buy: 1
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 29.3 | 26.1% |
P/E Trailing = 179.6154
P/E Forward = 8.0192
P/S = 1.2503
P/B = 1.4135
P/EG = 11.2121
Revenue TTM = 734.9m USD
EBIT TTM = 27.2m USD
EBITDA TTM = 118.4m USD
Long Term Debt = 367.7m USD (from longTermDebt, last quarter)
Short Term Debt = 9.82m USD (from shortTermDebt, last quarter)
Debt = 454.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 43.5m
Net Debt = 252.5m USD (calculated: Debt 454.7m - CCE 202.2m)
Enterprise Value = 1.17b USD (918.8m + Debt 454.7m - CCE 202.2m)
Interest Coverage Ratio = 1.83 (Ebit TTM 27.2m / Interest Expense TTM 14.9m)
EV/FCF = 8.83x (Enterprise Value 1.17b / FCF TTM 132.7m)
FCF Yield = 11.33% (FCF TTM 132.7m / Enterprise Value 1.17b)
FCF Margin = 18.06% (FCF TTM 132.7m / Revenue TTM 734.9m)
Net Margin = 0.70% (Net Income TTM 5.14m / Revenue TTM 734.9m)
Gross Margin = 79.34% ((Revenue TTM 734.9m - Cost of Revenue TTM 151.9m) / Revenue TTM)
Gross Margin QoQ = 79.47% (prev 79.53%)
Tobins Q-Ratio = 0.97 (Enterprise Value 1.17b / Total Assets 1.21b)
Interest Expense / Debt = 3.28% (Interest Expense 14.9m / Debt 454.7m)
Taxrate = 41.66% (2.08m / 5.00m)
NOPAT = 15.9m (EBIT 27.2m * (1 - 41.66%))
Current Ratio = 4.73 (Total Current Assets 515.0m / Total Current Liabilities 108.8m)
Debt / Equity = 0.70 (Debt 454.7m / totalStockholderEquity, last quarter 653.9m)
Debt / EBITDA = 2.13 (Net Debt 252.5m / EBITDA 118.4m)
Debt / FCF = 1.90 (Net Debt 252.5m / FCF TTM 132.7m)
Total Stockholder Equity = 708.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.37% (Net Income 5.14m / Total Assets 1.21b)
RoE = 0.57% (Net Income TTM 5.14m / Total Stockholder Equity 904.4m)
RoCE = 2.14% (EBIT 27.2m / Capital Employed (Equity 904.4m + L.T.Debt 367.7m))
RoIC = 1.53% (NOPAT 15.9m / Invested Capital 1.04b)
WACC = 3.53% (E(918.8m)/V(1.37b) * Re(4.33%) + D(454.7m)/V(1.37b) * Rd(3.28%) * (1-Tc(0.42)))
Discount Rate = 4.33% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.67 | Cagr: -10.16%
[DCF] Terminal Value 73.10% ; FCFF base≈143.4m ; Y1≈125.7m ; Y5≈101.6m
[DCF] Fair Price = 35.02 (EV 1.63b - Net Debt 252.5m = Equity 1.38b / Shares 39.3m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -16.04 | EPS CAGR: -1.31% | SUE: 0.26 | # QB: 0
Revenue Correlation: 98.82 | Revenue CAGR: 3.52% | SUE: 1.03 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.65 | Chg30d=-8.11% | Revisions=-40% | Analysts=7
EPS next Quarter (2026-09-30): EPS=0.77 | Chg30d=+10.66% | Revisions=+20% | Analysts=7
EPS current Year (2026-12-31): EPS=2.88 | Chg30d=+9.27% | Revisions=+40% | GrowthEPS=+8.5% | GrowthRev=+5.5%
EPS next Year (2027-12-31): EPS=3.64 | Chg30d=+3.79% | Revisions=+40% | GrowthEPS=+26.6% | GrowthRev=+8.4%
[Analyst] Revisions Ratio: -40%